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Graphical abstract: 
 
Abstract: 
Meloxicam is an anti-inflammatory drug that could be interesting to deliver locally to the 
lungs to treat inflammation occurring in cystic fibrosis or chronic obstructive pulmonary 
disease (COPD). Spray drying conditions were optimized to prepare inhalable dry powders, 
from meloxicam aqueous solution with pH adjustment. A comparison study between non-
porous and large porous particles (LPPs) was carried out to demonstrate the relevance of the 
aimed large size (>5 µm) and low density (<0.2 mg/cm
3
) formulations. With the appropriate 
amount of porogen agent, ammonium bicarbonate, LPPs exhibited the same aerodynamic 
diameter and a higher deposited fraction than smaller but dense particles. The aerodynamic 
evaluation of LPPs showed that the fine particle fraction (FPF) reached up to 65.8%, while the 
emitted fraction (EF) reached 85.4%, both higher than for the non-porous particles. Stability 
tests demonstrated that, after 10 weeks of storage, no significant difference could be detected 
in the aerodynamic behaviour of the formulations. To the best of our knowledge this is the 
first time large porous particles, with enhanced aerodynamic properties, from an aqueous 
solution of meloxicam are reported. 
Footnote 
AB – Ammonium Bicarbonate 
API – Active Pharmaceutical Ingredient 
CF – Cystic Fibrosis 
COPD – Chronic Obstructive Pulmonary Disease 
D[0.5] – Median Geometric Diameter 
DPI – Dry Powder Inhaler 
EF – Emitted Fraction 
FPF – Fine Particle Fraction 
HA – Sodium Hyaluronate 
LEU – L-Leucine 
LPPs – Large Porous Particles 
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MMAD – Mass Median Aerodynamic Diameter 
MX – Meloxicam 
NSAID – Non Steroidal Anti-Inflammatory Drug 
SD – Spray Dried 
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1 Introduction 
In the past decades, carrier-free dry powder inhalers (DPIs) have shown promises for the local 
pulmonary treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis 
(CF). In carrier-free formulations, active pharmaceutical ingredients (APIs) and excipients are 
formulated together into the inhalable DPI form without using large carriers such as lactose 
(Hoppentocht et al., 2014). 
For pulmonary disorders with increased inflammation, the use of non-steroidal anti-
inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, gained the attention of research 
studies (Szabó-Révész, 2018). Among NSAIDs, meloxicam (MX) is a low water-soluble 
cyclooxygenase enzyme-2 selective inhibitor, which has anti-inflammatory and antioxidant 
effects. Due to these effects, MX could be of interest for pulmonary administration to locally 
treat CF, COPD or any other lung inflammation (Tsubouchi et al., 2000; Arafa et al., 2007). 
So far, literature data reported preparation of MX containing inhalable microparticles by pre-
suspension spray drying method. Pomázi et al. described the preparation MX particles 
suspended in an aqueous solution of excipients (mannitol, poly-vinyl-alcohol, 
polyvinylpyrrolidone and leucine) which was then spray dried at 130 °C to produce inhalable 
microparticles with enhanced aerodynamic properties (Pomázi et. al., 2011; Pomázi et al, 
2013; Pomázi et al, 2014). Due to the preparation method, MX was in crystalline form in the 
formulations. Another option for the inhalable microcomposite preparation is the use of MX 
potassium salt form and additional excipients (Poly-vinyl alcohol, leucine) (Chvatal et al, 
2017). Due to the water solubility of the MX salt (Mezei et al., 2009), an easier feed stock 
preparation and spray drying conditions could be developed, leading to amorphous MX 
(Chvatal et al., 2017). 
The newest DPI researches report about several high potency carrier-free formulations 
prepared by spray drying. Co-spray drying has been widely used in the DPI production 
because it is scalable and offers an easily controlled particle formulation. Besides using this 
process for the micronization of the API, it can also lead to good aerodynamic properties for 
products (Healy et al., 2014). Innovative formulations by spray drying can be produced to 
create special structure (e.g. porous particles) and appropriate morphology of the API both for 
carrier-based and for carrier-free formulations (Tsapis, 2014). 
Carrier-free formulation aimed to reduce the intrinsic cohesion of the particles, increase 
dispersion and delivery from the inhaler. Special excipients are used (for e.g. amino acids, 
polymers, bulking agents, phospholipids) in the particle design phase to implement also low 
density and enhanced aerosolization of the particles (Healy et al., 2014). 
Among widely used excipients to increase the aerosolization behaviour of the particles are 
leucine (LEU) and its analogues such as tri-Leucine (Lechuga-Ballesteros et al, 2008; 
Vehring, 2008). LEU was shown to promote good aerosolization of the particles by 
decreasing the surface energy (cohesive and adhesive forces) between particles as it is 
accumulates at particle surface (Raula et al., 2010). It was also demonstrated that the LEU 
(above 20%, w/w content) may recrystallizes during the spray drying covering the surface of 
the particle and protecting it against moisture (Li et al., 2016). 
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Biodegradable polymers, such as sodium hyaluronate (HA), are also used to enhance the 
aerosolization of the API. HA can be used in the pulmonary drug delivery as a drug targeting, 
due to its mucoadhesive characteristics, absorption promoter and structure stabilizing effect 
(Martinelli et al., 2017). HA also increases the viscosity of the primary solution to obtain 
large droplets for spray drying and thus larger particle sizes. 
The aerodynamic performance of the DPIs also depends on the density of the powder. 
Particles with low density have better flowability and can be delivered to the lung easier with 
higher deposition (Bosquillon et al., 2001). An exact density value is not clearly established, 
but most of the studies consider the DPI ”low density” from a tap density around 0.4-0.1 
g/cm
3 
or lower (Ogienko et al., 2017; Ógáin et al., 2011; Watts et al., 2013). Large porous 
particles (LPPs) can be obtained using porogen agents (e.g. volatile liquids, ammonium 
carbonate or bicarbonate) in the primary solutions or emulsions (Gervelas et al., 2007). The 
porogen evaporates quicker than the dispersion phase is drying, leaving holes in the interior of 
the larger sized particles (N’Guessan et al., 2018; Pham et al., 2013). The formulation of 
stable structured LPPs with the appropriate excipient-API concentration and production 
properties may be the challenge of the pharmaceutical technology.  
We aimed to produce LPPs from MX aqueous solution by forming an MX salt at high pH. For 
this, we have optimized the spray drying procedure, by varying the solution excipient 
concentration. The planned LPPs with particle size larger than 5 µm and tap density lower 
than 0.25 g/cm
3
 should be endowed with enhanced aerosolization properties (Cruz et al., 
2011). The efficacies of the prepared LPPs were compared with non-porous formulations by 
their spray drying yield, physical chemical properties, morphology and in vitro aerodynamic 
behaviour. To the best of our knowledge, no other studies on the formulation of inhalable 
LPPs containing MX from solution exist. 
2 Materials and methods 
2.1 Materials 
Meloxicam (MX) was obtained from Egis Plc (Hungary). L-Leucine (LEU) and ammonium 
bicarbonate (AB) were purchased from Sigma-Aldrich (France) and sodium hyaluronate (HA) 
from Acros Organics (Belgium). Sodium hydroxide was obtained from Sigma-Aldrich 
(France). Water was purified using a RIOS/MilliQ system from Millipore (France). 
2.2 Preparation of the spray dried microparticles 
MX exhibits a pH dependent solubility: in buffers at pH 7.4-7.7 MX demonstrates almost 43 
fold solubility (1.74±0.2 mg/mL, 37 °C) at this pH than in distilled water (0.04±0.01 mg/mL, 
37 °C) (Horváth et al, 2016). Due to this characteristic, MX was dissolved at room 
temperature (18-20 °C) at higher pH, stabilized with 1 M sodium hydroxide aqueous solution, 
to prepare a stock solution for the spray drying. First, MX was dissolved in the high pH water 
(8.00±0.1 pH, stirring for 2 hours, 600 rpm) at a constant concentration of 1.5 mg/mL for each 
formulation. Secondly, in the MX solution, LEU was dissolved (15 min, 600 rpm) to reach a 
final concentration of 0.75 mg/mL. In some cases, HA was added to finally yield a HA 
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concentration of 0.15, 0.30 or 0.45 mg/mL (HA solutions were prepared the day before spray 
drying, stirring for 24 hours, 400 rpm). These solutions containing MX, MX+LEU or 
MX+LEU+HA were used for the formulation of non-porous particles. For LPP formulations, 
different concentrations of AB were added (0.5, 1.5 and 2.0 mg/mL) which functions as 
porogen agent as it decomposes into CO2 and H2O upon heating. AB was dissolved 5 min 
before the spray drying (stirring for 2 min, 200 rpm) to minimize its decomposition prior to 
spray drying. The inhalable microparticles were produced by spray drying using a Büchi B-
290 spray dryer equipped with a 0.7 mm two-fluid nozzle (Büchi, Switzerland). Drying 
properties were the followings: 200 °C inlet temperature, 9 mL/min feed pump rate (30%), 
100% aspirator rate, and 414 L/h gas flow rate. 
The spray drying yield was calculated as a percentage by dividing the mass of the powder 
collected from the container by the initial mass of solids in the solution prepared for drying. 
Prepared powders were stored in desiccator containing cobalt crystals to decrease moisture 
uptake (at 23±1 °C). 
2.3 Identification of spray dried API 
To investigate the characteristics of the API in the formulations, Raman spectroscopy was 
applied using Thermo Fisher DXR Dispersive Raman with CCD camera (Thermo Fisher Sco. 
Inc., Waltham, MA, USA). Following parameters were used during measurements: laser 
diode operating at a wavelength of 780 nm; the applied laser power was 6-24 mW at 25 µm 
slit aperture size on a 2 µm spot size; spectra were collected with 6 sec exposure time of 20 
scanning in the spectral range of 3300-200 cm
-1
. Reference sample, MX-recrystallized, was 
obtained with dissolving MX with the same method as MX solutions were prepared for spray 
drying. 1.5 mg/mL MX was dissolved in 8±0.1 pH sodium hydroxide aqueous solution 
(stirring for 2 hours, 600 rpm) and dried out at 40 °C, for 24 hours to study the changes during 
dissolution. 
The actual API content (%) after spray drying was measured by dissolving 1.0-1.1 mg 
formulation in 25 ml of methanol:pH 7.4 phosphate buffer (60:40%, v/v), which solution was 
used for the aerodynamic assessment also. Solutions were mixed for 10 min, 600 rpm and API 
content was quantified by UV/Vis spectrophotometry (ATI-UNICAM UV/VIS 
Spectrophotometer, Cambridge, UK) at 362 nm wavelength. Each sample was measured in 
triplicate. The calibration curve y= 0.00465x, R
2
=0.9994 was used for quantification. Values 
LOD (0.037 µg/mL) and LOQ (0.124 µg/mL) were also established. 
2.4 Morphology 
Scanning electron microscopy (SEM) (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan) 
was used to characterize the morphology of the spray dried formulations, applying 10 kV high 
voltage and 1.3-13.0 mPa air pressure. A high vacuum evaporator and argon atmosphere was 
used to sputter-coat samples with gold-palladium in order to make them conductive (Bio-Rad 
SC 502, VG Microtech, Uckfield, UK). 
7 
 
2.5 Particle size distribution 
The geometric diameter of the particles was established using laser diffraction (Mastersizer 
2000 equipped with a Sirocco dry disperser, Malvern Instruments, France). For the 
measurements a micro size plate was used at a dispersing pressure of 2 bars. Each sample was 
measured in triplicate. The particle size distribution was characterized by the D[0.1] (10% of 
the volume distribution is below this value), D[0.5] (the volume median diameter is the 
diameter where 50% of the distribution is above and 50% is below) and D[0.9] (90% of the 
volume distribution is below this value) values. The size distribution Span was calculated 
according to Eq. 1. A high Span value denotes a broad particle size distribution. The higher 
the Span value, the broader the particle size distribution is (Li et al., 2004). All samples were 
measured in triplicate. 
 (Eq. 1) 
2.6 Density measurements 
The density of the formulations was measured using a 5 mL cylinder, filled with 2-4 mL 
powder (for bulk density) and tapped 1000 times (for tap density) using a tapping apparatus 
(Pharma test PT-TD1) (European Pharmacopeia 9
th
 edition). All samples were measured in 
triplicate. 
2.7 Structural analyses 
To establish the crystalline or amorphous character of the spray dried samples, X-ray powder 
diffraction (XRPD) spectra were recorded with a BRUKER D8 Advance X-ray diffractometer 
(Bruker AXS GmbH, Karlsruhe, Germany) system with Cu Kα1 radiation (λ = 1.5406 Å) 
over the interval 3-40°. Measurement conditions were as follows: target, Cu; filter, Ni; 
voltage, 40 kV; current, 40 mA; time constant, 0.1 s; angular step 0.010°. 
2.8 Aerodynamic assessment 
The aerosolization efficacy of the spray dried formulations was assessed in vitro, using an 
Andersen cascade impactor - Apparatus D, (European Pharmacopeia 9
th
 edition), Copley 
Scientific, Switzerland). The inhalation flow rate was set at 30±1 L/min (High-capacity Pump 
Model HCP5, Critical Flow Controller Model TPK, Copley Scientific Ltd., Nottingham, UK). 
The inhalation time was 4 s for one inhalation simulation. Breezhaler® single dose devices 
were used, with size 3 capsules (transparent, Capsugel) filled with 2-2.5 mg of powder 
(constantly for each formulation). The inhaler was actuated twice for each capsule. The plates 
of the impactor were coated with 1 % w/v mixture of Span 85 and cyclohexane, to allow for 
the attachment of floating particles. After actuation, the inhalation device, the capsules, the 
induction port, the collection plates and the filter were washed with methanol:pH 7.4 
phosphate buffer (60:40 %, v/v) to collect and dissolve the deposited API. The collected MX 
was quantified by UV/Vis spectrophotometry (ATI-UNICAM UV/VIS Spectrophotometer, 
Cambridge, UK) at 362 nm wavelengths. 
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Aerodynamic properties (Fine particle fraction – FPF and Mass median aerodynamic diameter 
– MMAD) were calculated from a plot of the cumulative percentage undersize of API on log 
probability scale against the effective cut-off aerodynamic diameter (Colombo et al., 2012). 
The emitted fraction (EF) was expressed as the percentage of the API found in the cascade 
impactor (except the API found in the capsules and device) after inhalation relative to the total 
loaded dose. 
All the samples were measured at the 1
st
 week after the spray drying and after 10 weeks of 
storage. Samples were stored at room temperature (23±1 °C), in a separate desiccator 
containing cobalt crystals to assess for their stability. Each sample was measured in triplicate. 
Statistical analyses were taken for the stability assessment using t-test calculation, 0.05 
significance level and one-tailed hypothesis. 
3 Results and discussion 
Formulations were prepared according to Table I, by fixing MX concentration and varying the 
content in LEU and HA. In addition, non-porous particles (no AB added) were compared to 
LPPs prepared with AB. 
Table I. Composition of the solutions prepared for spray drying (mg/mL) and the 
compositions of the spray dried products (%). MX=meloxicam, LEU=leucine, HA=sodium 
hyaluronate and AB=ammonium bicarbonate. 
Sample names MX LEU HA AB* 
Non-porous particles 
MX-SD 
1.5 mg/mL 
(100%) 
- - - 
MX/LEU 
1.5 mg/mL 
(66.7%) 
0.75 mg/mL 
(33.3%) 
- - 
MX/LEU/HA
0.3
 
1.5 mg/mL 
(58.8%) 
0.75 mg/mL 
(29.4%) 
0.30 mg/mL 
(11.8%) 
- 
MX/LEU/HA
0.15
 
1.5 mg/mL 
(62.5%) 
0.75 mg/mL 
(31.2%) 
0.15 mg/mL 
(6.3%) 
- 
Large porous particles 
MX/LEU/HA
0.3
/AB
1.5
 
1.5 mg/mL 
(58.8%) 
0.75 mg/mL 
(29.4%) 
0.30 mg/mL 
(11.8%) 
1.5 
MX/LEU/HA
0.15
/AB
1.5
 
1.5 mg/mL 
(62.5%) 
0.75 mg/mL 
(31.2%) 
0.15 mg/mL 
(6.3%) 
1.5 
MX/LEU/HA
0.3
/AB
2
 
1.5 mg/mL 
(58.8%) 
0.75 mg/mL 
(29.4%) 
0.30 mg/mL 
(11.8%) 
2.0 
MX/LEU/HA
0.15
/AB
2
 
1.5 mg/mL 
(62.5%) 
0.75 mg/mL 
(31.2%) 
0.15 mg/mL 
(6.3%) 
2.0 
*AB is not present in the dried samples as it decomposes into CO2 and H2O during spray 
drying. 
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3.1 Identification of API and drug content in the spray dried formulations  
 
Fig. 1. Raman spectra of the raw MX (MX-raw), MX dissolved in sodium hydroxide at 1.5 
mg/mL and dried out at 40 °C, 24 hours (MX-recrystallized) and spray dried MX (MX-SD). 
The Raman spectrum of MX-raw exhibits characteristic bands at 1155, 1309, 1540 and 1595 
cm
-1
 (Fig. 1.). MX-recrystallized shows difference at the 1390 cm
-1
 compared to MX-raw 
where this band is missing. However, there is no difference in the spectra of the spray dried 
and the recrystallized samples. These Raman spectra are similar to the spectra of MX sodium 
salt according to Bio-Rad Laboratories database (Bio-Rad Laboratories, Inc. SpectraBase; 
Meloxicam sodium). Based on this result it was established that during dissolution of MX (at 
pH 8±0.1 in sodium hydroxide aqueous solution) MX sodium salt form was obtained. 
 
Fig. 2. Comparison of the Raman spectra of the spray dried MX (MX-SD) and one of the LPP 
formulations (MX/LEU/HA
0.3
/AB
2
). 
Spray dried MX (MX-SD) and formulations with excipients (Fig. 2. MX/LEU/HA
0.3
/AB
2 
LPP 
formulation
 
presented) exhibit the same spectra as MX sodium salt with characteristic Raman 
bands at 1390 and 1595 cm
-1
, indicating MX sodium salt form is present in spray dried 
formulations. 
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3.2 Particle morphology 
 
Fig. 3. Scanning Electron Microscopy pictures of the non-porous particles (A: MX-SD, B: 
MX/LEU, C: MX/LEU/HA
0.3
, D: MX/LEU/HA
0.15
) and large porous particles (E: 
MX/LEU/HA
0.15
/AB
1.5
, F: MX/LEU/HA
0.15
/AB
2
, G: MX/LEU/HA
0.3
/AB
1.5
, H: 
MX/LEU/HA
0.3
/AB
2
). 
From the SEM pictures, one can observe that the excipient free sample (A: MX-SD) exhibits 
a slightly rough surface and spherical-like shape (Fig. 3.). The same surface morphology was 
obtained with the spray drying of meloxicam potassium salt from aqueous solution (Chvatal 
et al., 2017). In other studies, the spray drying of meloxicam from aqueous suspension 
resulted in smooth surface particles with around 19 µm size (Pomázi et al, 2011). The 
presence of LEU increased the roughness of the surface and resulted in irregular-shaped 
particles (B: MX/LEU, C: MX/LEU/HA
0.3
, D: MX/LEU/HA
0.15
). The shape modification can 
be explained by the crystallization of LEU on droplet surface forming an external shell which 
collapses during the spray drying process (Vehring, 2008). The surface accumulation of LEU 
and the resulting rough surface may reduce the adhesion between particles and the attachment 
to capsule or inhalation device walls, leading to higher EF or FPF values (Aquino et al, 2012; 
Mangal et al., 2015). With 0.15-0.30 mg/mL HA content (C: MX/LEU/HA
0.15
 and D: 
MX/LEU/HA
0.3
) the particles kept similar wrinkled surfaces and the polymer has no visible 
impact on the morphology. However, literature data report that sodium hyaluronate could 
promote surface roughness of spray dried salbutamol sulphate particles (Li et al., 2017). LPPs 
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exhibit significantly different morphology than non-porous formulations proving the essential 
role of the porogen agent AB. The SEM pictures further demonstrated the porogen effect of 
AB, which was an essential excipient for LPP formulation. Samples MX/LEU/HA
0.15
/AB
1.5 
(E), MX/LEU/HA
0.15
/AB
2 
(F), MX/LEU/HA
0.3
/AB
1.5 
(G) and MX/LEU/HA
0.3
/AB
2
 (H)
 
present spherical shaped large sized particles. However the surface roughness of LPPs was 
much lower, slight wrinkles can be detected on the surface of the spherical particles. This 
change in shape could arise from the gas formation from AB during the drying procedure, 
which blows up the wrinkled structure (Fig. 3). This effect of AB is a well described in 
literature (Cruz et al., 2011; Nolan et al., 2009; Gervelas et al., 2007). Some of the broken 
shells demonstrate the internal hollow structure which reflects the porosity and low density. 
3.3 Size distribution 
Despite all the powders were prepared using similar drying parameters, the final particle size 
distributions were different (Table II.). The geometric diameter of spray dried MX was 
around 3 µm, nearly the same as the sample prepared with LEU (MX-SD 3.2 µm and 
MX/LEU 3.4 µm). Incorporating 0.75 mg/mL LEU in the formulation did not increase the 
geometric size of the MX containing particles as reported with other MX formulations using 
0.6 g/L or higher LEU concentrations (Pham et al, 2013; Chvatal et al, 2017). Studies with 
different active ingredients also showed no effect of leucine concentration on particle size up 
to 20% w/w (Aquino et al, 2012) or only a low effect up to 15% w/w (Mangal et al, 2015). 
We demonstrated that the particle size is slightly increasing with an increasing amount of HA: 
from 3.4 µm up to 4.3 µm with 0.30 mg/mL HA. In case of LPPs the geometric size was also 
increased significantly with the higher HA concentration (from 5.0 µm to 5.6 µm with 0.15 
and 0.30 mg/mL HA concentrations respectively). This increase probably arises from an 
increase of the viscosity of the spray dried solution leading to larger droplets and thus 
resulting in larger particle size. Li et al. also demonstrated that increased sodium hyaluronate 
concentration increases the particle size of co-spray dried salbutamol sulphate formulations 
from 3.8 µm up to 4.8 µm (0.20 and 0.35% w/w HA concentrations respectively) (Li et al, 
2017). With addition of AB to the LEU and HA combination, we obtained the aimed larger 
geometric diameter (larger than 4.9 µm) due to the formation of pores (blowing effect) of AB, 
as AB decomposes into water and gas during the drying process (Cruz et al., 2011; Pham et 
al, 2015). No evident effect on the geometric size was detected comparing 1.5 and 2.0 mg/mL 
AB concentrations. Both non-porous particles and LPPs have narrow size distribution with 
Span ≤2.0. No significant differences were detected between the geometric diameter of the 
particles measured at 1
st
 week and 10 weeks after of storage. 
3.4 Density of the spray dried microparticles 
As expected, non-porous particles have higher density than LPPs. Comparing the tap and bulk 
density, it can be established, that the difference between tap and bulk density of LPPs is 
lower than the difference between the same parameters for non-porous particles. This lower 
tap-bulk density differences indicates the better rearrangement of LPPs upon tapping. Briefly, 
from the density of the spray dried MX (MX-SD) and the formulation with 0.75 mg/mL of 
LEU (MX/LEU) it is clear that the presence of LEU increased the tap density from 0.36 up to 
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0.45 g/cm
3
 (Table II.). However, the bulk densities of these two formulations were similar 
(0.23 and 0.27 g/cm
3
). This can be explained with the rough surface LEU-containing 
particles: particles with rough surface or wrinkled shape can pack more efficiently and result 
in higher tap density (Simon et al., 2016). Our results were similar with previous observations 
where leucine inclusion up to 15% (w/w) led to higher bulk density powders while up to 20% 
(w/w) produced powders with similar or slightly lower bulk density (Aquino et al, 2012). 
Results show that the HA content has no relevant influence on the density of the powders. 
Despite the fact that HA is increasing the viscosity of solutions, it has no significant effect on 
the density of dried particles. Without AB all the samples containing HA (MX/LEU/HA
0.15
 
and MX/LEU/HA
0.3
) had a tap density around 0.42-0.47 g/cm
3
. Low density of LPPs is 
related to the AB content which leads to the formation of a porous structure as it decomposes 
upon drying. The 2.0 and 1.5 mg/mL AB content have almost the same density decreasing 
effect and all the following samples (MX/LEU/HA
0.15
/AB
1.5
, MX/LEU/HA
0.15
/AB
2
, 
MX/LEU/HA
0.3
/AB
1.5
 and MX/LEU/HA
0.15
/AB
2
) reach tap density <0.19 g/cm
3
. 
 
  
Table II. Compositions of the non-porous and large porous particles, prepared with the optimized spray drying conditions (200 °C inlet 
temperature, 100% aspirator capacity, 9 mL/min feed pump rate, and 414 L/h gas flow rate), the spray drying characteristics (API content and 
spray drying yield), size distribution (D[0.5] = Median geometric diameter and Span) and density properties (bulk and tap density). Data are 
represented as mean ±S.D., n=3. 
Sample names 
Spray drying 
yield (%) 
Final API 
content (%) D[0.5] (µm) Span 
Bulk density 
(g/cm
3
) 
Tap density 
(g/cm
3
) 
Non-porous particles 
MX-SD 88±2.76 89.7±1.3 3.2±0.08 1.4±0.08 0.23±0.02 0.36±0.06 
MX/LEU 84±2.25 67.1±1.1 3.4±0.02 1.5±0.01 0.27±0.01 0.45±0.05 
MX/LEU/HA
0.3
 59±5.49 57.2±0.2 4.3±0.01  1.7±0.11 0.28±0.01 0.47±0.03 
MX/LEU/HA
0.15
 64±6.62 62.0±0.3 3.9±1.07 1.7±0.03 0.27±0.01 0.42±0.10 
Large porous particles 
MX/LEU/HA
0.3
/AB
1.5
 62±2.13 53.6±2.1 5.6±0.73 2.0±0.10 0.09±0.01 0.14±0.01 
MX/LEU/HA
0.15
/AB
1.5
 67±2.39 55.3±0.3 5.0±0.60 1.9±0.22 0.09±0.01 0.15±0.01 
MX/LEU/HA
0.3
/AB
2
 62±2.07 50.7±1.0 5.6±0.64 2.0±0.13 0.07±0.02 0.10±0.02 
MX/LEU/HA
0.15
/AB
2
 68±3.75 58.7±1.6 4.9±0.60 1.9±0.31 0.10±0.02 0.19±0.05 
 
 3.5 Structural analyses 
 
Fig. 4. XRPD spectra: The crystalline raw MX (MX-raw), and LEU (LEU-raw) are compared 
with the spray dried sample (A), non-porous particles (B: MX/LEU, C: MX/LEU/HA
0.3
, D: 
MX/LEU/HA
0.15
) and LPPs (E: MX/LEU/HA
0.3
/AB
1.5
, F: MX/LEU/HA
0.15
/AB
2
, G: 
MX/LEU/HA
0.15
/AB
1.5
, H: MX/LEU/HA
0.3
/AB
2
). 
X-Ray powder diffraction was then used to characterize the crystalline state of MX after the 
spray drying process (Fig. 4.). The raw MX has characteristic peaks with the highest 
intensities at 6.6°, 11.4°, 13.1º, 13.5°, 15.1º, 18.7°, 19.3°, 25.9° and 26.4º 2-theta peaks 
indicating its crystalline structure (Aytekin et al., 2018). The fact that the characteristic peaks 
of crystalline MX are missing from the diffractogram of the spray dried sample (MX-SD) 
indicates that the raw material becomes amorphous when spray drying without excipients 
(Fig. 4. and Supplementary material S1). However, characteristic peaks of MX at 6.6°, 
11.4°, 13°, 13.6° and 19.2° 2-theta appear in the formulations containing LEU 
(Supplementary Material S1), indicating a low level of crystallinity. We detected the same 
characteristic peaks of LEU that literature data reported (Najafabadi et al., 2004; Li et al., 
20016; Chvatal et al., 2017). The characteristic peak 5.9° 2-theta of LEU could be observed 
on the spectra of the formulations but broader and with much lower intensity. These low 
intensity peaks demonstrate the low crystallinity of LEU after spray drying. The presence of 
HA has no effect on the diffractogram of the samples. 
3.6 Aerodynamic properties 
The aerodynamic properties (EF, FPF and MMAD) of powders were tested at 1
st
 week and 10 
weeks after the spray drying. No significant difference can be detected in the EF, FPF and 
 MMAD of the samples comparing the properties at 1
st
 week and after 10 weeks storage 
(desiccator, 23±1 °C). The aerodynamic properties of the spray dried formulations remain 
unchanged.  
An effect of excipients was observed for the non-porous formulations: those prepared with 
LEU have significantly higher EF than MX-SD. LEU increases the EF from ≤53.6% to 
≥57.1%. LEU not just minimized the cohesion between particles, but also reduces the 
attachment to capsule wall during inhalation which resulted in higher EF values (Aquino et al, 
2012; Mangal et al., 2015). However, contrary to other results showing that surface roughness 
lead to an increased FPF for LEU containing corrugated particles (Chew et al, 2005), we did 
not detect the FPF increasing effect of LEU. For the non-porous particles, the FPF remained 
in the 35-41% range independently of the excipients.  
There are significant differences in the aerodynamic properties of LPPs and non-porous 
particles. LPPs result in higher EF and FPF than non-porous formulations (Table III). 
Briefly, the EF of the non-porous particles is not exceeding 62.1%, while LPPs EF are above 
76.1% in all cases. The high EF of LPPs is related to the good flowability of particles and low 
adhesion to the capsule and device walls. It can be demonstrated, that the used AB 
concentrations have a relevant effect on the aerodynamic behaviour of LPPs. LPPs have 
significantly lower tap density (comparing to non-porous particles) which resulted improved 
lung deposition (FPF 54.5-65.8%). Bosquillon et al also established the same correlation 
between density and aerodynamics: the lower the tap density (0.04–0.25 g/cm3), the higher 
the FPF (Bosquillon et al, 2001). LPP formulations prepared with 1.5 mg/mL AB 
concentrations have lower FPF (≤57.4%) than formulations containing 2.0 mg/mL AB 
(≥59.7%). The increased AB concentration (2.0 mg/mL) resulted in the highest FPF with 
65.8% in case of MX/LEU/HA
0.15
/AB
2
 (measured at the 1
st
 week). Despite the significant 
effect on the FPF, AB concentration has no significant effect on the EF of the LPPs. 
Comparing the LPP formulations, it can be concluded that HA content has no significant 
effect on the EF or FPF. 
  
 Table III. Comparison of the aerodynamic properties of the non-porous and large porous 
particles tested at 1
st
 week and 10 weeks after spray drying simulating a 30 L/min inhalation 
flow rate. EF = emitted fraction, FPF = fine particle fraction. Data are represented as mean 
±S.D., n=3. 
Sample names 
1
st
 week 10
th
 week 
EF (%) FPF (%)* EF (%) FPF (%)* 
Non-porous particles 
MX-SD 53.6±10.5 38.6±4.7 50.4±6.7 37.9±4.8 
MX/LEU 61.7±4.1 41.2±3.3 59.9±8.1 39.7±1.7 
MX/LEU/HA
0.3
 57.1±1.8 36.2±4.2 61.5±3.8 36.8±3.1 
MX/LEU/HA
0.15
 59.9±1.7 35.6±2.7 62.1±2.9 35.9±2.6 
Large porous particles 
MX/LEU/HA
0.3
/AB
1.5
 79.5±4.2 54.5±2.1 79.4±2.3 55.9±2.3 
MX/LEU/HA
0.15
/AB
1.5
 77.5±6.8 57.4±5.6 76.1±9.9 54.5±10.1 
MX/LEU/HA
0.3
/AB
2
 79.5±5.5 59.7±4.0 85.4±3.2 60.5±1.6 
MX/LEU/HA
0.15
/AB
2
 82.8±6.8 65.8±3.2 82.3±8.3 63.0±4.5 
*FPF (<5 µm) was expressed with reference to the loaded dose. 
The presented low density LPPs (≤0.19 g/cm3) have better aerosolization properties 
(EF≥76.1% and FPF≥54.5%) and can reach the lower airways more easily than the smaller 
but denser non-porous particles (EF≤62.1% and FPF≤41.2%). Figure 5 demonstrates the 
relevance of the large geometric diameter (>5 µm) and low density (<0.25 g/cm
3
) LPPs for 
lung delivery (Fig. 5.). LPPs and non-porous particles result in the same MMAD values 
(average 2.55 µm) with no significant differences. However, LPPs have larger geometric 
diameter (≤4.9 µm) than non-porous formulations. In case of non-porous formulations the 
increasing D[0.5] resulted in larger MMADs. In case of LPPs the MMAD is not increasing 
with the D[0.5]. Different effects were observed comparing the excipient concentrations just 
in case of LPPs. LPPs with 2.0 mg/mL AB concentration exhibit lower MMAD (2.41-2.32 
µm) than those with 1.5 mg/mL (2.57-2.74 µm). The higher amount of porogen affected 
positively the flowability of the particles thus resulted in lower aerodynamic diameter. By 
contrast, there is no significant difference between the MMAD of 0.15 and 0.30 mg/mL HA 
concentrations. 
  
Fig. 5. Comparison of the aerodynamic and geometric diameter (MMAD = mass median 
aerodynamic diameter and D[0.5] = median geometric diameter) of the spray dried 
formulations. Data show the low density LPPs (E: MX/LEU/HA
0.3
/AB
1.5
, F: 
MX/LEU/HA
0.15
/AB
1.5
, G: MX/LEU/HA
0.3
/AB
2
 and H: MX/LEU/HA
0.15
/AB
2
) have the same 
or smaller MMAD than smaller but denser non-porous particles (A: MX-SD, B: MX/LEU, C: 
MX/LEU/HA
0.3
 and D: MX/LEU/HA
0.15
). Data are represented as mean ± S.D., n=3. 
4 Conclusions 
In the present study, two types of carrier-free DPIs were produced and compared: non-porous 
and LPP formulations of MX. We produced inhalable microparticles from MX aqueous 
solution with pH adjustment at pH 8±0.1, to facilitate the particle formulation process with in 
situ water soluble salt formation. Inhalable microparticles were produced with optimized 
spray drying conditions: 200 °C inlet temperature, 100% aspirator rate, 9 mL/min pump rate, 
and 414 L/h gas flow rate. LPPs with particle size larger than 4.9 µm and tap density lower 
than 0.19 g/cm
3
 were obtained using 1.5 mg/mL MX, with 0.75 mg/mL LEU, 0.15 and 0.3 
mg/mL HA; 1.5 and 2.0 mg/mL AB (samples MX/LEU/HA
0.3
/AB
1.5
, MX/LEU/HA
0.15
/AB
2
, 
MX/LEU/HA
0.15
/AB
1.5
 and MX/LEU/HA
0.3
/AB
2
). The aerosolization efficacies of the 
prepared LLPs were compared with the non-porous particles by testing the in vitro 
aerodynamical behaviour (with Andersen Cascade Impactor). The study was carried out using 
30 L/min to simulate the low inhalation flow rate characteristic of lung inflammation diseases. 
LPPs show EF above 77% and FPF above 54%, both exceeding the non-porous particles 
values. The aerodynamical properties remain unchanged after 10 weeks of storage for all 
formulations. The concentration of AB, a porogen agent used in the primary solutions is a 
critical parameter of the LPP formulation. The best considered LPPs (with the highest spray 
drying yield >66% and FPF reaching 69%) were the ones containing 2 mg/mL AB as porogen 
beside the appropriate concentration of LEU and HA (samples MX/LEU/HA
0.3
/AB
2
 and 
MX/LEU/HA
0.15
/AB
2
). The presented aerodynamic properties have no significant difference 
measured after 1 and 10 weeks of storage. Thanks to the good aerosolization properties, the 
presented LPPs containing MX may offer an effective local treatment for lung inflammation 
diseases and should be tested in vivo in a near future. 
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Figure S1: Zoom on the diffractograms of the spray dried samples (A), non-porous particles 
(B: MX/LEU, C: MX/LEU/HA
0.3
, D: MX/LEU/HA
0.15
) and LPPs (E: MX/LEU/HA
0.3
/AB
1.5
, 
F: MX/LEU/HA
0.15
/AB
2
, G: MX/LEU/HA
0.15
/AB
1.5
, H: MX/LEU/HA
0.3
/AB
2
). 
 
